Curriculum Vitaes
Profile Information
- Affiliation
- Associate Professor, Department of Internal Medicine, Neurology, Fujita Health University Okazaki Medical Center
- Degree
- 博士(医学)(藤田保健衛生大学)
- J-GLOBAL ID
- 201501008162133427
- researchmap Member ID
- 7000012808
Research Areas
1Papers
149-
Parkinsonism & related disorders, 131 107251-107251, Feb, 2025INTRODUCTION: Progressive supranuclear palsy (PSP) involves midbrain structures, including the red nucleus (RN), an iron-rich region that appears as a high-contrast area on quantitative susceptibility mapping (QSM). RN may serve as a promising biomarker for differentiating parkinsonism. However, RN deformation in PSP remains elusive. This study aimed to evaluate RN deformation in PSP using coronal QSM images and compare them with those of Parkinson's disease (PD) and healthy controls (HC). METHODS: We evaluated the QSM images of 22 patients with PSP, 37 patients with PD, and 43 HC. We developed a grading system to assess RN deformation on coronal QSM images and classified them into three grades. The midbrain and RN volumes were extracted using distinct approaches, and their relationship with grading was investigated. For validation, coronal QSM images of 16 PSP patients from a different institution were assessed. RESULTS: In PSP, 59 % of the patients displayed a flattened RN of grade 3, which we termed a Rice-Grain Appearance. The volume reductions in midbrain and RN were associated with deformation. Differentiation based on the presence of this appearance yielded a specificity of 1.000 (CI: 1.000-1.000) and sensitivity of 0.591 (0.385-0.796) for distinguishing PSP from others. Secondary dataset also showed that 56 % of patients with PSP were classified as grade 3. CONCLUSION: In coronal QSM images, the flattened RN shape appears to be specific to PSP compared to PD and HC and may serve as a marker to help differentiate PSP in future clinical settings.
-
Pediatrics international : official journal of the Japan Pediatric Society, 67(1) e15865, 2025
-
Emerging Infectious Diseases, 30(12), Dec, 2024
-
Journal of Parkinson's disease, 14(8) 1533-1542, Nov, 2024BACKGROUND: Recent evidence suggests a link between glycoprotein non-metastatic melanoma protein B (GPNMB) and Parkinson's disease (PD) pathogenesis. Although elevated plasma GPNMB levels associated with disease severity have been reported in PD, cerebrospinal fluid (CSF) alterations remain elusive. OBJECTIVE: To explore CSF GPNMB alterations and its clinical significance in PD. METHODS: This study enrolled 118 sporadic PD patients and 40 controls. We examined the potential associations between CSF GPNMB levels and the clinical characteristics or biomarkers of neurodegenerative pathogenesis. RESULTS: PD patients had higher CSF GPNMB levels than controls (p = 0.0159). In the PD group, CSF GPNMB levels correlated with age (age at examination: rs = 0.2511, p = 0.0061; age at onset: rs = 0.2800, p = 0.0021) and the severity of motor and cognitive dysfunction (MDS-UPDRS III score: rs = 0.1998, p = 0.0347; Mini-Mental State Examination score: rs = -0.1922, p = 0.0370). After correcting for multiple comparisons, the correlation with age at onset remained significant. CSF GPNMB levels were also positively correlated with CSF soluble triggering receptor expressed on myeloid cells 2 (sTREM2) levels in both the PD (rs = 0.3582, p < 0.0001) and control (rs = 0.4743, p = 0.0023) groups. Furthermore, multiple regression analysis revealed CSF sTREM2 level as the strongest determinant of CSF GPNMB levels in the PD group (t-value = 3.49, p = 0.0007). CONCLUSIONS: Elevated CSF GPNMB levels, linked with age and microglial activation, may be a valuable marker for understanding the interplay between aging, neuroinflammation, and PD pathology.
-
NPJ Parkinson's disease, 10(1) 170-170, Sep 9, 2024The relationship between reduced serum uric acid (UA) levels and Parkinson's disease (PD), particularly purine metabolic pathways, is not fully understood. Our study compared serum and cerebrospinal fluid (CSF) levels of inosine, hypoxanthine, xanthine, and UA in PD patients and healthy controls. We analyzed 132 samples (serum, 45 PD, and 29 age- and sex-matched healthy controls; CSF, 39 PD, and 19 age- and sex-matched healthy controls) using liquid chromatography-tandem mass spectrometry. Results showed significantly lower serum and CSF UA levels in PD patients than in controls (p < 0.0001; effect size r = 0.5007 in serum, p = 0.0046; r = 0.3720 in CSF). Decreased serum hypoxanthine levels were observed (p = 0.0002; r = 0.4338) in PD patients compared to controls with decreased CSF inosine and hypoxanthine levels (p < 0.0001, r = 0.5396: p = 0.0276, r = 0.2893). A general linear model analysis indicated that the reduced UA levels were mainly due to external factors such as sex and weight in serum and age and weight in CSF unrelated to the purine metabolic pathway. Our findings highlight that decreased UA levels in PD are influenced by factors beyond purine metabolism, including external factors such as sex, weight, and age, emphasizing the need for further research into the underlying mechanisms and potential therapeutic approaches.
Misc.
28-
Brain and nerve = Shinkei kenkyu no shinpo, 74(7) 879-884, Jul, 2022A group of patients with coronavirus disease 2019 (COVID-19) exhibited various persistent or new systemic symptoms, including psychiatric symptoms, sleep disturbances, exercise intolerance, arthralgia, headache, cognitive decline, brain fog, and autonomic symptoms, all of which persisted long after the resolution of infectious symptoms. Several imaging studies have shown that long COVID cases present with decreased glucose metabolism and progressive brain atrophy. Although no single pathological hypothesis thoroughly explains the varied clinical presentations and timings, the following have attracted attention: 1) persistent viral infection, 2) persistent inflammation, 3) involvement of the autoimmune system, and 4) mitochondrial dysfunction. In all these hypotheses, inflammatory cytokines may be involved in orthostatic dysregulation by decreasing the expression and activity of ACE2, consequently changing the blood pressure through vagus nerve hyperactivation. Myopathy and peripheral neuropathy may also be caused by direct infection of the muscles and nerves, hypoxia, mitochondrial damage, and cytokine storm. Furthermore, multiple theories regarding the mechanisms by which systemic inflammatory findings affect the central nervous system have been postulated, including neuroinflammation caused by inflammatory cells crossing the blood-brain barrier via choroid plexus cells and the involvement of various autoantibodies. Despite these findings, no definitive consensus has been reached due to the complexity and diversity of COVID-19 pathophysiology. Thus, it is essential to understand the neurological symptoms and pathophysiology involved in long COVID.
-
画像診断, 42(2) 145-155, Jan 25, 2022<文献概要>TDP-43は主に核内に存在し,RNAの生合成をはじめ様々なプロセスに関与する.TDP-43の核内局在の喪失と異常な翻訳後修飾を受けた不溶化TDP-43の存在を特徴とする一群は,TDP-43proteinopathyと呼ばれ,筋萎縮性側索硬化症と前頭側頭葉変性症が代表的な疾患である.
-
画像診断, 41(14) 1470-1481, Nov 25, 2021<文献概要>認知症の診断は,適切な病歴聴取,神経学的診察,高次脳機能評価,脳画像を評価することで行われる.最近は,血液や髄液のバイオマーカー開発も目覚ましい.脳画像を解釈する上で,認知症の臨床像の特徴,診断基準,臨床病型の多様性,高次脳機能検査結果の解釈方法などを整理することは有益である.
-
脊椎脊髄ジャーナル, 33(11) 1025-1030, Nov, 2020<文献概要>はじめに 日常臨床において,脊髄小脳路を侵す疾患を意識しながら診療をする場面は決して多くない.その理由を考えてみると,まず脊髄小脳路の重要な役割は筋紡錘や腱器官などから固有感覚を小脳へと伝えることにあるが,体性感覚の中でも,意識に上る表在感覚や,位置覚や振動覚など意識に上る深部感覚と違い,意識に上らない固有感覚の評価は,一般的な神経学的診察で困難であるため,固有感覚と密接に関連する脊髄小脳路病変を意識する機会が限られていることが挙げられる.次に,脊髄小脳路を正しく評価できる補助診断指標が日常臨床で十分に使えないことが挙げられる.脊髄小脳路の周囲には,皮質脊髄路,後索,後根を含めてさまざまな構造物があるため,固有感覚の障害による症状であるのか,ほかの運動系や感覚系の障害による症状であるのかを判断するためには画像検査が重要となるが,日常臨床においてMRIを用いて正確に脊髄小脳路と周囲の構造物とを明確に区別することは容易ではない.一方,体幹や下肢の運動失調の発現は後索の単独病変では生じず,後根や後根神経節,さらには脊髄小脳路などの障害が必要とする報告があること,姿勢の調節には下肢からの固有知覚信号が必要であることなどを踏まえると,脊髄小脳路病変を伴う疾患を知り,その臨床像を見直すことは重要である.そこで本稿では,ここで扱う脊髄小脳路の走行を簡単に整理したうえで,まず脊髄小脳路を侵す疾患として,物理的に脊髄小脳路を圧排した転移性脊髄腫瘍の臨床像や,比較的純粋な脊髄小脳路病変をみていると考えられる下部延髄外側梗塞症例の臨床像を整理する.さらに,脊髄小脳路を侵すことが報告されている非変性疾患と変性疾患について,誌面の許す範囲で整理し,今後の課題について考えてみる.
-
Neurological Therapeutics, 37(4) 513-516, Jul, 2020In Parkinson's disease, the progression of the clarification of cortico–basal ganglia loop based on the firing rate model has dramatically contributed to the development of not only medical and surgical treatments but also an understanding of side effects. On the other hand, progress in recent research has clarified the limitations of the firing frequency model and has shown the relationship between abnormal β band oscillations and pathological conditions that complements the limitations of the firing rate model. Besides, research on the elucidation of new pathological conditions using resting–state functional MRI analysis has also been in progress. This review summarizes recent advances in treatment strategies for Parkinson's disease that take into account brain network abnormalities.
-
ディサースリア臨床研究, 9(1) 23-28, Dec, 2019多系統萎縮症(MSA)は,病理学的にglial cytoplasmic inclusionの出現を特徴とする進行性の神経変性疾患で,パーキンソニズム,小脳失調,自律神経不全,錐体路徴候を経過中に種々の程度で認める.孤発性が圧倒的に多い.パーキンソニズムが優位な臨床病型はMSA-P,小脳失調が優位な臨床病型はMSA-Cと呼ばれる.欧米ではMSA-Pが多く,日本ではMSA-Cが多い.平均発症年齢は55〜60歳で,若年発症例や,75歳を超える高齢発症例もある.診断には運動機能異常(パーキンソン症状もしくは小脳性運動失調)と自律神経不全の存在が必須で,両系統の症状が揃うまでの期間の中央値は2年である.早期からのディサースリアや嚥下障害をはじめとするRed flagsサイン(診断を支持する特徴)にも留意する.頭部MRIのほか,Tilt試験,ウロダイナミックスタディ,123 I-metaiodobenzylguanidine(MIBG)心筋シンチグラフィーなどが補助検査として有用である.予後は6年から10年で,突然死が多いことが特徴であり,高度な自律神経不全は予後不良因子である.従来は稀と考えられていた認知症の合併をはじめ,多様な臨床病型を呈する一群のあることも明らかとなっている.(著者抄録)
-
月刊薬事 = The pharmaceuticals monthly, 61(11) 1921-1928, Aug, 2019
-
神経免疫学, 20(1) 99-99, Sep, 2015
Presentations
164Research Projects
4-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2021 - Mar, 2024
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2018 - Mar, 2021
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2015 - Mar, 2018
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2012 - Mar, 2015